Compare Crown Castle International Corp (CCI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Twist Bioscience Corp — how do they compare? Crown Castle International Corp trades at $79.34 (market cap $34.50B), while Twist Bioscience Corp trades at $92.63 (market cap $5.77B). The key difference: Crown Castle International Corp is far larger — about 6× Twist Bioscience Corp's market cap, and Crown Castle International Corp pays a 5.38% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CCI | TWST | |
|---|---|---|
Market Cap | $34.50B | $5.77B |
Sector | Real Estate | Health |
52-Week High | $113.91 | $102.88 |
52-Week Low | $74.92 | $24.16 |
Enterprise Value | $64.33B | $5.69B |
Dividend Yield | 5.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $79.84, up 0.23% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains strong profitability with a 73.82% gross margin. Recent news highlights its pure-play U.S. tower focus and upcoming Q2 2026 earnings call on July 22, 2026.
CCI presents a turnaround opportunity with analyst consensus targeting $97.33, implying 22% upside, but faces risks from high debt levels and volatile earnings. The stock's negative equity and bearish technicals warrant caution despite attractive dividend yield and cost reduction initiatives.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
